Author:
Duggan Sean,Al-Salama Zaina T.
Publisher
Springer Science and Business Media LLC
Reference10 articles.
1. Bloomfield M, Klocperk A, Zachova R, et al. Natural course of activated phosphoinositide 3-kinase delta syndrome in childhood and adolescence. Front Pediatr. 2021. https://doi.org/10.3389/fped.2021.697706.
2. Newman H, Teachey DT. PI3king apart a rare disease with targeted therapy. Blood. 2023;141(9):963–4.
3. Rao VK, Webster S, Dalm V, et al. Effective “activated PI3Kδ syndrome”-targeted therapy with the PI3Kδ inhibitor leniolisib. Blood. 2017;130(21):2307–16.
4. Rao VK, Webster S, Šedivá A, et al. A randomized, placebo-controlled phase 3 trial of the PI3Kδ inhibitor leniolisib for activated PI3Kδ syndrome. Blood. 2023;141(9):971–83.
5. Administration USFD. FDA approves first treatment for activated phosphoinositide 3-kinase delta syndrome [media release]. 24 Mar 2023. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-treatment-activated-phosphoinositide-3-kinase-delta-syndrome.
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献